Daily FNArena News

Permanent FDA approval has removed a major regulatory overhang for Bubs Australia while opening the door to further US distribution

Fairmont Equities’ Michael Gable believes the technical set-up for South32 shares is pointing to further upside

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is Macquarie Group

As Alpha HPA builds its new plant in Gladstone, AI investment is opening new semiconductor and thermal management markets

Higher bond yields are not necessarily part of the markets are breaking down narrative, says Mark Dowding, Chief Investment Officer, Fixed Income at RBC BlueBay Asset Management

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Nufarm’s guidance miss was largely due to two unplanned outages, now resolved, while record growth in Seeds more than offsets headwinds for Crop Protection

Telix Pharmaceutical’s proposed acquisition of a global isotope manufacturing supplier brings forth a strategically significant opportunity, although not without risks

Australian consumers are proving surprisingly resilient, but analysts warn higher rates, falling house prices and rising costs could increasingly test discretionary spending through FY27